摘要
目的分析呼吸道重症感染患者采取头孢哌酮钠他唑巴坦钠、左氧氟沙星联合治疗的临床效果。方法该次研究选取2015年1月-2018年12月于该院接受治疗的呼吸道重症感染患者110例作为观察对象,根据抽签结果分为观察组与对照组,对照组患者单纯以头孢哌酮钠他唑巴坦钠药物治疗,观察组患者在其基础上联用左氧氟沙星,对比两组治疗总有效率,记录并分析两组患者治疗前后血气分数指标差异,比较各组患者临床相关指标,计算不良反应总发生概率。结果观察组患者治疗总有效率(98.18%)明显优于对照组(85.45%),差异有统计学意义(χ^2=5.93,P<0.05)。经治疗后,观察组PaCO2(40.72±1.17)mmHg低于对照组,PaO2(84.21±2.04)mmHg高于对照组。观察组患者细菌检查结果转阴时间(7.49±1.14)d、症状彻底消失时间(6.02±1.12)d、治疗总时间(10.19±1.18)d均短于对照组(t=8.36、9.15、11.04,P<0.05)。结论呼吸道重症感染通过头孢哌酮钠他唑巴坦钠联合左氧氟沙星治疗效果更佳,可改善患者症状表现及血气指标,安全性好,值得推广。
Objective To analyze the clinical effects of combined treatment with cefoperazone sodium, tazobactam sodium and levofloxacin in patients with severe respiratory infection. Methods A total of 110 patients with severe respiratory infection who were treated in the hospital from January 2015 to December 2018 were enrolled. The observation group was divided into observation group and control group. The control group was treated with cefoperazone sodium and tazobactam. In the observation group, the patients in the observation group were combined with levofloxacin. The total effective rate of the two groups was compared. The differences of blood gas scores before and after treatment were recorded and analyzed. The clinically relevant indicators of each group were compared and the adverse reactions probability were calculated. Results The total effective rate of treatment in the observation group(98.18%) was significantly better than that in the control group(85.45%). The difference was statistically significant(χ^2=5.93, P<0.05). After treatment, PaCO2(40.72±1.17) mmHg was lower in the observation group than in the control group, and PaO2(84.21±2.04) mmHg was higher than the control group. The observation time of the patients in the observation group was negative(7.49 ±1.14) d, the time of complete disappearance of symptoms(6.02±1.12) d, and the total time of treatment(10.19±1.18) d were shorter than the control group(t=8.36, 9.15, 11.04, P <0.05). Conclusion Severe respiratory infection is better by cefoperazone sodium tazobactam sodium combined with levofloxacin, which can improve the patient’s symptoms and blood gas index. It is safe and worth promoting.
作者
葛雅香
王小军
GE Ya-xiang;WANG Xiao-jun(Department of Internal Medicine,Eighth People's Hospital,Tongzhou District,Nantong,Jiangsu Province,226361 China)
出处
《世界复合医学》
2019年第12期189-191,共3页
World Journal of Complex Medicine
关键词
头孢哌酮钠他唑巴坦钠
左氧氟沙星
呼吸道重症感染
疗效
Cefoperazone sodium tazobactam sodium
Levofloxacin
Severe respiratory infection
Efficacy
